Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

479 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Lactobacillus fermentum NCIMB 5221 and NCIMB 2797 as cholesterol-lowering probiotic biotherapeutics: in vitro analysis.
Tomaro-Duchesneau C, Saha S, Malhotra M, Jones ML, Rodes L, Prakash S. Tomaro-Duchesneau C, et al. Benef Microbes. 2015;6(6):861-9. doi: 10.3920/BM2015.0021. Epub 2015 Aug 31. Benef Microbes. 2015. PMID: 26322545
Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. reuteri NCIMB 30242.
Martoni CJ, Labbé A, Ganopolsky JG, Prakash S, Jones ML. Martoni CJ, et al. Gut Microbes. 2015;6(1):57-65. doi: 10.1080/19490976.2015.1005474. Gut Microbes. 2015. PMID: 25612224 Free PMC article. Clinical Trial.
Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial.
Jones ML, Martoni CJ, Prakash S. Jones ML, et al. J Clin Endocrinol Metab. 2013 Jul;98(7):2944-51. doi: 10.1210/jc.2012-4262. Epub 2013 Apr 22. J Clin Endocrinol Metab. 2013. PMID: 23609838 Clinical Trial.
Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications.
Jones ML, Tomaro-Duchesneau C, Martoni CJ, Prakash S. Jones ML, et al. Expert Opin Biol Ther. 2013 May;13(5):631-42. doi: 10.1517/14712598.2013.758706. Epub 2013 Jan 28. Expert Opin Biol Ther. 2013. PMID: 23350815 Review.
Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: a randomized, placebo-controlled, double-blind study.
Jones ML, Martoni CJ, Tamber S, Parent M, Prakash S. Jones ML, et al. Food Chem Toxicol. 2012 Jun;50(6):2216-23. doi: 10.1016/j.fct.2012.03.010. Epub 2012 Mar 15. Food Chem Toxicol. 2012. PMID: 22425689 Clinical Trial.
Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial.
Jones ML, Martoni CJ, Di Pietro E, Simon RR, Prakash S. Jones ML, et al. Regul Toxicol Pharmacol. 2012 Jul;63(2):313-20. doi: 10.1016/j.yrtph.2012.04.003. Epub 2012 Apr 25. Regul Toxicol Pharmacol. 2012. PMID: 22561556 Clinical Trial.
Probiotic Ferulic Acid Esterase Active Lactobacillus fermentum NCIMB 5221 APA Microcapsules for Oral Delivery: Preparation and in Vitro Characterization.
Tomaro-Duchesneau C, Saha S, Malhotra M, Coussa-Charley M, Kahouli I, Jones ML, Labbé A, Prakash S. Tomaro-Duchesneau C, et al. Pharmaceuticals (Basel). 2012 Feb 16;5(2):236-48. doi: 10.3390/ph5020236. Pharmaceuticals (Basel). 2012. PMID: 24288090 Free PMC article.
The use of simulated gastrointestinal conditions led to a significant 2.5 log difference in viability between the free (1.10 × 104 ± 1.00 × 103 cfu/mL) and the microencapsulated (5.50 × 106 ± 1.00 × 105 cfu/mL) L. fermentum NCIMB 5221 following exposure. ...
The use of simulated gastrointestinal conditions led to a significant 2.5 log difference in viability between the free (1.10 × 104 ± 1.00 × …
Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial.
Jones ML, Martoni CJ, Ganopolsky JG, Sulemankhil I, Ghali P, Prakash S. Jones ML, et al. Expert Opin Biol Ther. 2013 Dec;13(12):1643-51. doi: 10.1517/14712598.2013.833601. Epub 2013 Sep 28. Expert Opin Biol Ther. 2013. PMID: 24074303 Clinical Trial.
479 results
Jump to page
Feedback